Thermo Fisher Scientific (TMO): The company's Q3 2024 earnings came in above expectations, consequently causing an upgrade to a 'Buy' rating despite sales struggles at key units. TMO remains confident in delivering its 2024 goals even with mixed earnings. It has faced some challenges, including a breach of FDA rules at a plant producing an infant RSV drug. The recent earnings report caused fluctuations in the market, oscillating between stock falling and rising. The company's Q3 report suggests a strong financial performance yet there were slight misses on revenue. Trading escalated after the earnings release with a surge in share purchases by several financial entities. There was a consistent clash of predictions between beating estimates and underperforming the market. Forecast upgrades were made due to strong demand for its products and services. Despite this, Leerink Partners projects a negative Q4 outlook for TMO. The stock remains attractive to investors with several hedge funds increasing their holdings. However, concerns regarding the company's Greenville plant report have emerged. As an innovative contribution, TMO launched an advanced Analytical Scanning Transmission Electron Microscope for Materials Science research.
Thermo Fisher Scientific TMO News Analytics from Tue, 21 May 2024 07:00:00 GMT to Sat, 26 Oct 2024 14:37:45 GMT -
Rating 2
- Innovation 3
- Information 8
- Rumor -3
